Radnor biotech firm wins U.S. grant

PolyMedix Inc., Radnor, said today it received a $986,000 federal grant to develop medicines to treat an infection of the oral cavity called oral candidiasis.

The infection, which can be life-threatening, is caused by overgrowth of a yeast fungus, PolyMedix said.

The funding, the second the company has won from the National Institutes of Health, will cover research through August 2012.

PolyMedix is a publicly traded biotechnology company developing drugs to treat acute cardiovascular disorders and infectious diseases.    -Paul Schweizer